Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Preliminary Efficacy of Sm-p80 + GLA-SE (SchistoShield®) Vaccine Against Controlled Human Schistosome Infection in Healthy, Schistosoma-naïve Adults

NCT05999825 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT05999825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05999825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Preliminary Efficacy of Sm-p80 + GLA-SE (SchistoShield®) Vaccine Against Controlled Human Schistosome Infection in Healthy, Schistosoma-naïve Adults
Lead sponsor
Leiden University Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2024
Completion date
September 30, 2025
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schistosoma mansoni, schistosomiasis